{
    "root": "2d94ce8d-5992-45c0-bf59-a8e12d226462",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250311",
    "ingredients": [
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "GLYCERYL TRIACETYL 12-HYDROXYSTEARATE",
            "code": "2VX7GXC26Y"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X"
        },
        {
            "name": "MYRRH OIL",
            "code": "H74221J5J4"
        },
        {
            "name": "BALSAM PERU OIL",
            "code": "DIK0395679"
        },
        {
            "name": "ANISYL ALCOHOL",
            "code": "7N6XGV3U49"
        },
        {
            "name": "ACETOIN",
            "code": "BG4D34CO2H"
        },
        {
            "name": "FUSEL OIL",
            "code": "2NK7O363Q6"
        },
        {
            "name": "CITRONELLIC ACID",
            "code": "1JJT408R87"
        },
        {
            "name": "BENZOIN ACETATE",
            "code": "8KD59RC90V"
        },
        {
            "name": "2,3-PENTANEDIONE",
            "code": "K4WBE45SCM"
        },
        {
            "name": "DECANOIC ACID, 1-METHYLBUTYL ESTER",
            "code": "59VBP7Z87U"
        },
        {
            "name": "OCTANOIC ACID",
            "code": "OBL58JN025"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "ORANGE OIL",
            "code": "AKN3KSD11B"
        },
        {
            "name": "ETHYL BUTYRATE",
            "code": "UFD2LZ005D"
        },
        {
            "name": "ISOAMYL ACETATE",
            "code": "Z135787824"
        },
        {
            "name": "CITRAL",
            "code": "T7EU0O9VPP"
        },
        {
            "name": "GERANIOL",
            "code": "L837108USY"
        },
        {
            "name": "CITRONELLOL ACETATE, (R)-",
            "code": "9X45FJL446"
        }
    ],
    "indications": "amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml indicated treatment pediatric patients aged 3 months 12 years weighing less equal 40 kg : recurrent persistent acute otitis media due s. pneumoniae ( penicillin mics less equal 2 mcg/ml ) , h. influenzae ( including beta-lactamase-producing strains ) , m. catarrhalis ( including beta-lactamase-producing strains ) characterized following risk factors : antibacterial exposure acute otitis media within preceding 3 months , either following : 1 ) age 2 years , younger 2 ) day care attendance [ microbiology ( 12.4 ) ] . limitations amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml indicated treatment acute otitis media due s. pneumoniae penicillin mic greater equal 4 mcg/ml . acute otitis media due s. pneumoniae alone treated amoxicillin . therapy may instituted prior obtaining results bacteriological reason believe infection may involve s. pneumoniae ( penicillin mic less equal 2 mcg/ml ) beta-lactamase-producing organisms listed . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml antibacterial drugs , amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "\u2022 pediatric patients aged 3 months 12 years weighing less equal 40 kg : 90 mg/kg/day divided every 12 hours , administered 10 days . ( 2 )",
    "warningsAndPrecautions": "supplied color dry powder amoxicillin clavulanate potassium oral suspension usp , 600 mg/42.9 mg per 5 ml white creamy white powder . vanilla tutti frutti-flavored powder oral suspension . following constitution , 5 ml oral suspension contains 600 mg amoxicillin trihydrate 42.9 mg clavulanic acid potassium salt ( equivalent 51.1 mg clavulanate potassium ) . ndc 73043 008 01 , 75 ml bottlendc 73043 008 02 , 125 ml bottlendc 73043 008 03 , 200 ml bottle . storage store reconstituted suspension refrigeration . discard unused suspension 10 days . store dry powder 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense original container . keep tightly closed . keep medications reach children .",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium oral suspension , 600 mg/42.9 mg per 5 ml . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL is indicated for the treatment of pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg with:\n                  \n                     Recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs less than or equal to 2 mcg/mL), H. influenzae (including beta-lactamase-producing strains), or M. catarrhalis (including beta-lactamase-producing strains) characterized by the following risk factors:\n                           Antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see Microbiology (12.4)].\n                        \n                     \n                  \n                  \n                     Limitations of Use\n                  \n                  Amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC greater than or equal to 4 mcg/mL. Acute otitis media due to S. pneumoniae alone can be treated with amoxicillin. Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC less than or equal to 2 mcg/mL) and the beta-lactamase-producing organisms listed above.\n                  \n                     Usage\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL and other antibacterial drugs, Amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "\u2022 Pediatric Patients aged 3 months to 12 years weighing less than or equal to 40 kg: 90 mg/kg/day divided every 12 hours, administered for 10 days. ( 2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  The color of the dry powder for amoxicillin and clavulanate potassium for oral suspension USP, 600 mg/42.9 mg per 5 mL is white to creamy white powder.\n                  Vanilla and tutti frutti-flavored powder for oral suspension. Following constitution, each 5 mL of oral suspension contains 600 mg of amoxicillin as the trihydrate and 42.9 mg of clavulanic acid as the potassium salt (equivalent to 51.1 mg of clavulanate potassium).\n                  NDC 73043 008 01, 75 mL bottleNDC 73043 008 02, 125 mL bottleNDC 73043 008 03, 200 mL bottle.\n                  \n                     Storage\n                  \n                  Store reconstituted suspension under refrigeration. Discard unused suspension after 10 days. Store dry powder at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature]. Dispense in original container. Keep tightly closed.\n                  Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 mL. ( 4.2 )"
}